ESPR vs KEYS · rev $332.3M vs P/E 57, rev $4.98B
Esperion Therapeutics Inc (ESPR) versus Keysight Technologies Inc (KEYS) — a side-by-side from cached financials, not a winner call.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Keysight Technologies Inc (KEYS) is a scientific & technical instruments company listed on US.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
Latest reported KEYS revenue for 2024-10-31 was $4.98B. Net income was $614.0M. Revenue was down 8.9% from 2023-10-31 to 2024-10-31. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
ESPR currently screens at market cap $816.9M. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
Not investment advice. Open the ESPR and KEYS stock pages for the full models.
Not investment advice.